LYKALABS vs MEDICO: Stock Comparison

Lyka Labs Limited vs Medico Remedies Limited

Live data: 1 July 2026, 4:08 PM IST • Source: NSE and company filings

Medico Remedies Limited is the larger company by market capitalisation. Lyka Labs Limited shows a lower P/E and lower leverage, while Medico Remedies Limited shows a higher ROE, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Lyka Labs Limited and Medico Remedies Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, LYKALABS is more favourable on 3 of 13 scored metrics and MEDICO on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
MEDICO is the larger company
₹317 Cr vs ₹226 Cr
P/E Ratio
LYKALABS has a lower P/E
-20.64x vs 27.22x
P/B Ratio
LYKALABS has a lower P/B
2.24x vs 4.73x
EPS
MEDICO has higher earnings per share
₹1.58 vs ₹-2.81
Revenue Growth (TTM YoY)
MEDICO has faster revenue growth
37.5% vs 0%
EPS Growth (TTM YoY)
MEDICO has faster EPS growth
36.5% vs 0%
Qtr Sales Growth
MEDICO has stronger quarterly sales growth
37.6% vs 9.7%
Qtr Profit Growth
MEDICO has stronger quarterly profit growth
35% vs -35.4%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricLYKALABSMEDICO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricLYKALABSMEDICO
Live Price₹74.83₹38.38
Day Change1.19%-0.62%
Volume88,55616,597
52-Week High₹121.44₹56.88
52-Week Low₹44.1₹30.22
Distance from 52W High-38.38%-32.52%

Valuation

MetricLYKALABSMEDICO
Market Cap₹226 Cr₹317 Cr
P/E Ratio-20.64x27.22x
P/B Ratio2.24x4.73x
EPS₹-2.81₹1.58
Book Value₹25.87₹9.15
Dividend Yield0%0%

Growth

MetricLYKALABSMEDICO
Revenue Growth (TTM YoY)0%37.5%
EPS Growth (TTM YoY)0%36.5%
Qtr Sales Growth9.7%37.6%
Qtr Profit Growth-35.4%35%

Profitability & Leverage

MetricLYKALABSMEDICO
ROE0%19%
ROCE9.91%23.1%
Net Margin-7.81%6.36%
Operating Margin-9.43%8.25%
Debt to Equity0x0.25x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricLYKALABSMEDICO
Promoter Holding58.16%61.38%
FII Holding0.29% 0.12 pp0.03% 0.46 pp
DII Holding0.67%0%
Public Holding40.88% 0.12 pp38.59% 0.46 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Lyka Labs Limited and Medico Remedies Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.